{
  "id": 14797120,
  "title": "William Blair initiates Cytokinetics stock coverage with outperform rating",
  "url": "https://urgent.news/2026/10/15/william-blair-initiates-cytokinetics-stock-coverage-with-outperform",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-15T21:36:52.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/william-blair-initiates-cytokinetics-stock-coverage-with-outperform-rating-93CH-4952733"
  },
  "original_language": "en",
  "account": "Investing.com reports that William Blair has started covering Cytokinetics Inc (NASDAQ:CYTK) with an Outperform rating and a price target of $101 per share. Based on discounted cash flow valuation, this represents an 58% upside from the current stock price of $63.92, which is close to InvestingPro's Fair Value estimate of $62.94. The bullish outlook aligns with Wall Street consensus, with analysts holding a Strong Buy rating and price targets ranging from $85 to $146. William Blair is confident in the commercial launch of MYQORZO, the company's first approved product, through 2027. The specialty cardiology company generated $67.67 million in revenue over the last year, but analysts don't anticipate profitability this year. Cytokinetics maintains a strong current ratio of 6.66, indicating sufficient liquidity to fund its expansion. The firm anticipates approval for nHCM around mid-2027, which would add approximately 100,000 addressable patients to the market opportunity. By 2032, Cytokinetics projects sales of around $3.74 billion. Key risks include the MYQORZO commercial launch, regulatory matters, and clinical execution. Recent developments have put Cytokinetics in the spotlight, with UBS lowering its price target to $104 while maintaining a Buy rating, Cantor Fitzgerald reiterating an Overweight rating, and Truist Securities setting a $112 price target. Cytokinetics has also filed a declaratory judgment action against Bristol-Myers Squibb and MyoKardia, disputing a U.S. patent's validity. H.C. Wainwright recently renewed its Buy rating with a $140 price target following this legal move.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}